Actively Recruiting
Pilot Study of Oral Microbiota Therapy to Treat Primary Sclerosing Cholangitis in Adults Ages 18 to 76
Led by University of Minnesota · Updated on 2026-05-20
28
Participants Needed
1
Research Sites
22 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the initial safety and feasibility of microbiota transplant therapy MTT in patients with primary sclerosing cholangitis PSC, a liver disease. This early-phase pilot trial aims to gather information that will help design future studies for treating PSC. The study is sponsored by the University of Minnesota and focuses on exploring this new treatment approach. Participants will receive an antibiotic preconditioning regimen consisting of oral vancomycin 500 mg liquid twice daily for 28 days and oral amoxicillin 1000 mg twice daily for 7 days overlapping with the last week of vancomycin. Following this, a freeze-dried microbiota preparation MTP-101C is given orally as capsules, with five capsules daily for 3 days, then two capsules daily for 11 days, totaling 14 days of treatment and 37 capsules overall. During the trial, participants will be monitored for safety and how well they tolerate the therapy over 221 days. Researchers will assess outcomes such as adverse effects and feasibility of the treatment. Participants will have follow-up visits and communications via telephone, in-person, email, or video during the study period. The study includes baseline imaging and lab tests to ensure eligibility and monitor health status throughout the trial.
CONDITIONS
Brief Title
Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC
Research Team
A
Amanda Kabage
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here